Sorafenib as an Inhibitor of RUVBL2

por Nano, Nardin, Ugwu, Francisca, Seraphim, Thiago V., Li, Tangzhi, Azer, Gina, Isaac, Methvin, Prakesch, Michael, Barbosa, Leandro R. S., Ramos, Carlos H. I., Datti, Alessandro, Houry, Walid A.
Publicado 2020

PI3K/AKT/mTOR inhibition in combination with doxorubicin is an effective therapy for leiomyosarcoma

por Babichev, Yael, Kabaroff, Leah, Datti, Alessandro, Uehling, David, Isaac, Methvin, Al-awar, Rima, Prakesch, Michael, Sun, Ren X., Boutros, Paul C., Venier, Rosemarie, Dickson, Brendan C., Gladdy, Rebecca A.
Publicado 2016

The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia

por Edilova, Maria I., Law, Jaclyn C., Zangiabadi, Safoura, Ting, Kenneth, Mbanwi, Achire N., Arruda, Andrea, Uehling, David, Isaac, Methvin, Prakesch, Michael, Al-awar, Rima, Minden, Mark D., Abdul-Sater, Ali A., Watts, Tania H.
Publicado 2021

Structure and mechanism of action of the hydroxy aryl aldehyde class of IRE1 endoribonuclease inhibitors

por Sanches, Mario, Duffy, Nicole M., Talukdar, Manisha, Thevakumaran, Nero, Chiovitti, David, Canny, Marella D., Lee, Kenneth, Kurinov, Igor, Uehling, David, Al-awar, Rima, Poda, Gennadiy, Prakesch, Michael, Wilson, Brian, Tam, Victor, Schweitzer, Colleen, Toro, Andras, Lucas, Julie L., Vuga, Danka, Lehmann, Lynn, Durocher, Daniel, Zeng, Qingping, Patterson, John B., Sicheri, Frank
Publicado 2014